Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)

PLoS ONE(2024)10.1371/journal.pone.0302998Source: DataRank Database

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam) is a research paper published in PLoS ONE (2024). On theSindex it has a DataRank of 0.319. It has been cited 4 times, with 4 citing works in its 1-hop citation network.

N/A

0.319DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access4 citations · 4 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT06223360

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.09)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 76%Citation Network 24%

Base Score Contribution

0.241

From this paper's citation signal

Citation Network Contribution

0.0776

From 4 citing papers with measurable signal

Learn more about DataRank methodology →

Top 4 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 4 citers.

Ethnic differences in thiamine status persist after adjusting for diet; findings from the UK National Diet and Nutrition Survey
Clinical Nutrition ESPEN20262 citations18 referencesContributes 0.061
Glycation in Alzheimer’s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions
Molecular Neurobiology202513 citations189 referencesContributes 0.014
Cerebral glucose uptake and cognitive functions: A phenome-wide Mendelian randomization study
Journal of Alzheimer s Disease20261 citations51 referencesContributes 0.014
Vitamin deficiencies and Alzheimer’s disease: evidence and implications for supplementation
Frontiers in Nutrition20261 citations251 referencesContributes 0.003

Authors (20)

José A. Luchsinger ORCID,Gabriel C. Léger ORCID,Curtis Taylor,Diane M. Jacobs ORCID,David P. Salmon ORCID

Live enrichment

PubMed:38809849 PMC:PMC11135745 OpenAlex:https://openalex.org/W4399126031

National Institute on Aging

Grant: R01AG076634

NIA NIH HHS

Grant: R01 AG072505

NIA NIH HHS

Grant: P30 AG062429

European Commission

Grant: 860197

Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis

National Institutes of Health

Grant: 4R44AG059489-02

Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis

National Institutes of Health

Grant: 5R01AG076634-02

Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease

European Commission

Grant: 101053962

Fluid Biomarkers for Neurodegenerative Dementias

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01AG072505-05

Apolipoprotein E glycosylation and its role in Alzheimer's disease pathogenesis

National Institutes of Health

Grant: 1R01AG082228-01A1

Mechanistic links between the benefits of pharmacologically high thiamine (vitamin B1) in Alzheimer's disease to Advanced Glycation Endproducts (AGE)

FWCI

1.09

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302998&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302998&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0302998

journalhttps://doi.org/10.1371/journal.pone.0302998

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38809849

Fields of Study

Alcoholism and Thiamine DeficiencyAlzheimer's disease research and treatmentsBiochemical Acid Research Studies03 medical and health sciences0302 clinical medicineAgedFemaleHumansMaleMiddle AgedAlzheimer DiseaseDouble-Blind MethodProdrugsThiamineTreatment OutcomeClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

MeSH Terms

AgedAlzheimer DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedProdrugsThiamineRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase II as Topic

Keywords

Randomized controlled trialMedicinePlaceboDouble blindProtocol (science)Alzheimer's diseaseInternal medicinePharmacologyDiseasePathologyAlternative medicineMaleScienceQR610Middle AgedStudy ProtocolTreatment OutcomeClinical Trials, Phase II as TopicDouble-Blind MethodAlzheimer DiseaseHumansFemaleProdrugsThiamineAgedRandomized Controlled Trials as Topic

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being